Methamphetamine Use Disorder – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Methamphetamine use disorder refers to the illicit use of methamphetamines as a drug of abuse. It is a cationic lipophilic molecule that stimulates the release, and partially blocks the reuptake, of newly synthesized catecholamines in the CNS (Cho and Melega, 2002). Due to its structural similarity, methamphetamine substitutes for the dopamine transporter (DAT), noradrenaline transporter (NET), serotonin transporter (SERT), and vesicular monoamine transporter-2 (VMAT-2) and reverses their endogenous function, thereby redistributing monoamines from storage vesicles into the cytosol. Further, the majority of individuals admitted to treatment were non-Hispanic White (69%), followed by individuals of Mexican origin.
Methamphetamine
dependence is largely a disorder of the White population; however, this may be
a byproduct of the regional variability in methamphetamine use, which is
currently greatest in the West and parts of the Midwest.
The rates
of methamphetamine dependence appear to be roughly equivalent in men compared
to women, with 53% of primary methamphetamine/amphetamine admissions being
male.
The competitive
landscape of Methamphetamine Use Disorder includes country-specific approved and
pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Methamphetamine
Use Disorder across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Methamphetamine
Use Disorder Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 IXT-m200 InterveXion
Therapeutics, LLC Phase 2
2 Acamprosate Forest
Laboratories Phase 1/2
3 Naltrexone: Vivitrol® The
Emmes Company, LLC Phase 3
4 Naltrexone Alkermes,
Inc. Phase 2
Comments
Post a Comment